1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Mustang’s CAR-T MB-106 Shows Potential Competitiveness In CD20 Space

 
• By Alaric DeArment

The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.

Editorial use only - ARCADIA, CA - MAR 20: Horses break from the gate in an allowance race at Santa Anita Park on Mar 20, 2010 in Arcadia, CA
Mustang Bio announced data from the Phase I/II study of the anti-CD20 CAR-T therapy MB-106 in B-cell malignancies • Source: Shutterstock

The field of therapeutics for B-cell malignancies that target the CD20 antigen has become a crowded space, but Mustang Bio Inc. is developing an autologous chimeric antigen receptor T-cell (CAR-T) therapy that has a chance to stand out with early data showing a high response rate in patients, including those who previously received CAR-T cells.

Mustang announced data 25 April from a Phase I/II study of MB-106, a CD20-directed autologous CAR-T therapy that the company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 
• By Alaric DeArment

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 
• By Dexter Jie Yan

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 
• By Dexter Jie Yan

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

More from Anticancer

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By Joseph Haas

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.